Fig. 1

Clemastine treatment up to postnatal day 120 prolongs survival in SOD1-G93A mice. a Schematic representation of experimental in vivo design. b Short and long clemastine treatments delay disease onset of SOD1-G93A mice by 8 days (128 days for short treatment, 127 days for long treatment vs 120 days for vehicle) (p ≤ 0.05). c Body weight and d behavioural scores are improved in clemastine short treatment (red line), but not in long treatment (blue line), with respect to vehicle mice (black line) (*p ≤ 0.05). WT mice (green line). Short clemastine-treated mice show a significant difference in the time to reach a 25 % (e) and a 50 % (f) grip strength impairment, with respect to vehicle-treated SOD1-G93A mice (p < 0.05). g Short clemastine-treated mice (red line) show a significant difference in median survival, with respect to vehicle-treated SOD1-G93A mice, as shown by Kaplan–Meier survival curves (186 days for clemastine vs 170 days for vehicle; p < 0.05). Long clemastine-treated mice (blue line) show no significant differences in median survival with respect to vehicle-treated SOD1-G93A mice, as shown by Kaplan–Meier survival curves (160 days for clemastine vs 160 days for vehicle). WT group, n = 6 mice; vehicle- and long clemastine-treated groups, n = 12 mice/group; short clemastine-treated, n = 6 mice